GM-CSF secreting leukemia cell vaccination for MDS/AML after allogeneic HSCT: a randomized, double-blinded, phase 2 trial.

Blood Adv · 2022 · PMC9006263 · PMID 34807983

Europe PMC DOI

hedged sentence

0.0900

closest p · 1.8× alpha

0.0900

boldest claim

The sentences

did not reach statistical significanceP = .09so close (0.05 < p ≤ 0.1)

The 3-year estimate for relapse was also lower: 10% (95% confidence interval, 0.5-37) among the low GM-CSF vaccine recipients vs 47% (95% confidence interval, 19-70) in the high GM-CSF–secreting vaccine recipients, although this did not reach statistical significance ( P = .09).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.